Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 6/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | KATNA1 | O75449 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781531 | 0.90 | DYRK1A (0.45) | DYRK1AATMFGFR1KATNA1HTT | |
| SCHEMBL21449908 | 0.90 | DYRK1A (0.55) | DYRK1AATMFGFR1KATNA1CYP11B2 | |
| SCHEMBL21449929 | 0.86 | GABRP (0.45) | DYRK1AATMFGFR1KATNA1 | |
| SCHEMBL19781256 | 0.83 | FGFR1 (0.48) | DYRK1AATMFGFR1HTTCYP11B2 | |
| SCHEMBL19781608 | 0.81 | FGFR1 (0.46) | DYRK1AATMFGFR1HTTCYP11B2 | |
| SCHEMBL19781259 | 0.76 | FGFR1 (0.47) | ATMFGFR1HTTCYP11B2MAPT | |
| SCHEMBL19781511 | 0.76 | FGFR1 (0.59) | ATMFGFR1HTTCYP11B2MAPT | |
| SCHEMBL19781537 | 0.75 | KCNH2 (0.55) | FGFR1HTTCYP11B2MAPTKDM4E | |
| SCHEMBL7382437 | 0.75 | CYP1A2 (0.41) | DYRK1AATMWDR5MAPTTP53 | |
| SCHEMBL30269616 | 0.74 | DYRK1A (0.59) | DYRK1AATMFGFR1KATNA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | DYRK1A 4561/4885ATM 4747/4885FGFR1 3928/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | DYRK1A 4561/4885ATM 4747/4885FGFR1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.